We are live on ! Find out more
RETA

Reata Pharmaceuticals, Inc. Class A Common Stock
RETA

Delisted

RETA was delisted on the 25th of September, 2023.

Back to rankings

2 hedge funds and large institutions have $2.98M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 210 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% less call options, than puts

Call options by funds: $16.5M | Put options by funds: $50.7M

99% less funds holding

Funds holding: 214 → 2 (-212)

100% less capital invested

Capital invested by funds: $3.21B → $2.98M (-$3.21B)

100% less funds holding in top 10

Funds holding in top 10: 8 → 0 (-8)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 210

Holders
2
Holders Change
-212
Holders Change %
-99.07%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
210
Calls
$16.5M
Puts
$50.7M
Net Calls
-$34.3M
Net Calls Change
-$53.4M

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CI
CPMG Inc
Texas
-$295M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$288M
3
BlackRock
BlackRock
New York
-$259M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$180M
5
Deutsche Bank
Deutsche Bank
Germany
-$152M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
101
Capital Counsel
New York
– -$1.73M -17,000 Closed
Citigroup
102
Citigroup
New York
– -$1.67M -16,422 Closed
Manulife (Manufacturers Life Insurance)
103
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$1.64M -16,068 Closed
Federated Hermes
104
Federated Hermes
Pennsylvania
– -$1.61M -15,756 Closed
KeyBank National Association
105
KeyBank National Association
Ohio
– -$1.55M -15,250 Closed
MIM
106
MetLife Investment Management
New Jersey
– -$1.54M -15,065 Closed
Stifel Financial
107
Stifel Financial
Missouri
– -$1.53M -14,983 Closed
WC
108
Woodstock Corp
Massachusetts
– -$1.46M -14,285 Closed
Franklin Resources
109
Franklin Resources
California
– -$1.44M -14,166 Closed
AIG
110
American International Group
New York
– -$1.4M -13,757 Closed
Mirae Asset Global Investments
111
Mirae Asset Global Investments
South Korea
– -$1.31M -12,838 Closed
Wells Fargo
112
Wells Fargo
California
– -$1.3M -12,783 Closed
BIA
113
Biondo Investment Advisors
Pennsylvania
– -$1.3M -12,750 Closed
CAPTRUST Financial Advisors
114
CAPTRUST Financial Advisors
North Carolina
– -$1.28M -12,545 Closed
SCM
115
Silverarc Capital Management
Massachusetts
– -$1.27M -12,500 Closed
New York State Common Retirement Fund
116
New York State Common Retirement Fund
New York
– -$1.18M -11,526 Closed
IWC
117
Integrated Wealth Concepts
Massachusetts
– -$1.14M -11,171 Closed
PCM
118
Prelude Capital Management
New York
– -$1.08M -10,550 Closed
HF
119
HRT Financial
New York
– -$1.03M -10,069 Closed
MCM
120
Moore Capital Management
New York
– -$1.02M -10,000 Closed
US Bancorp
121
US Bancorp
Minnesota
– -$905K -8,875 Closed
State Board of Administration of Florida Retirement System
122
State Board of Administration of Florida Retirement System
Florida
– -$828K -8,117 Closed
GS
123
GTS Securities
New York
– -$799K -7,833 Closed
Allianz Asset Management
124
Allianz Asset Management
Germany
– -$744K -7,300 Closed
Two Sigma Advisers
125
Two Sigma Advisers
New York
– -$734K -7,200 Closed
3 4
5
6 7

RETA Hedge Fund Activity: Q3 2023 in Review

2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2023, worth a combined $2.98M — down 100% from $3.21B a quarter earlier.

Sellers outnumbered buyers: 210 funds closed out of RETA and 0 opened new positions — a net loss of 210 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was CPMG Inc, exiting entirely with an estimated $295M sold.

  • 2 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2023, down from 214 in Q2 2023.
  • Funds reported $2.98M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2023 and 210 closed out, a net change of -210 holders.
  • The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2023 was CPMG Inc, an estimated $295M sold.

Based on aggregated 13F filings for Q3 2023.